Reduction of Immunosuppression for Transplant-Associated Skin Cancer: Rationale and Evidence of Efficacy

Otley, Clark C.; Maragh, Sherry L.H.

doi:10.1111/j.1524-4725.2005.31038

Cited by 58 publications

(54 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cyclosporine is associated with SCC development in a dose dependent manner, and combination with azathioprine and prednisone is associated with a 3-fold higher risk of skin cancer versus azathioprine and prednisone alone [33][34][35] . Although tacrolimus is a calcineurin inhibitor, the risk of SCC is not as high as with cyclosporine 36 . The most frequently used immunosuppressive regimen in our patients was a combination of mycophenolate mofetil, tacrolimus and prednisone.…”

Section: Discussionmentioning

confidence: 99%

Clinical Findings, Treatments and Outcomes of Transplant Recipients with Metastatic Skin Cancer

2017

ARC Journal of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Clinical Findings, Treatments and Outcomes of Transplant Recipients with Metastatic Skin Cancer

2017

ARC Journal of Dermatology

View full text Add to dashboard Cite

“…The mortality rate for skin cancers in SOTR is anywhere between 5 and 8 %, and the risks are augmented with factors such as the impact of the human papilloma virus (HPV) and cumulative UVA/B exposure [24,25].…”

Section: P Leucotomos: Photoprotection Versus Chemopreventionmentioning

confidence: 99%

Polypodium leucotomos: A Potential New Photoprotective Agent

Bhatia

2015

Am J Clin Dermatol

View full text Add to dashboard Cite

As the understanding of the immune system pathways, cytokine balances, and cellular interactions continues to expand, so must the potential applications of therapies that can impact the process of diseases instead of just controlling their symptoms. In the case of Polypodium leucotomos extract, which is derived from a tropical fern of the Polypodiaceae family, the future potential of applications in dermatology and beyond will be better understood as its incorporation into daily routines gives rise to the development of new regimens. Clinicians may position this agent as an option for daily maintenance, accept its use in combinations, or use it as a template for further development of oral supplementation that may evolve into a true immunomodulator. The antioxidant activity of P. leucotomos extract is primarily driven by caffeic acid and ferulic acid, resulting in the control of cutaneous responses to ultraviolet-induced erythema, in the interception of inflammatory mechanisms, and the promotion of other cytotoxic responses. Histologically, the impact of P. leucotomos extract induces an effect on the overall reduction of angiogenesis, photocarcinogenesis, and solar elastosis, while on the cellular level there are improvements in cell membrane integrity and elastin expression. Future applications for P. leucotomos extract could include the potential for photoprotective effects, and subsequent research efforts should focus on determining the optimal dosage regimen, duration of action, and utility of combinations with sunscreens, among other outcomes. Recently published data have also demonstrated how the antioxidant effects of oral P. leucotomos extract can delay tumor development in mice models, suggesting there might be a protective role that could be described with further clinical research. In addition, it is important to recognize the distinction between photoprotection and chemoprevention, in that there has yet to be any in vivo or controlled clinical trial data in human subjects that show a role for P. leucotomos extract in the prevention of carcinogenesis.

show abstract

“…Kliniske studier har vist at risikoen for hudkreft øker generelt med mer effektiv immunsuppresjon og med behandlingsvarighet (6,23). Noen hudsvulster er vist å gå tilbake etter seponering av immunsuppresjon (24). Risikoen for virusassosierte kreftformer går ned etter avsluttet immunsuppresjon ved tap av nyretransplantat (25).…”

Section: åRsaker Til Hudkreft Ved Immunsuppresjonunclassified

Immunsuppressive legemidler og utvikling av hudkreft etter organtransplantasjon

Gjersvik¹,

Helsing²,

Holdaas³

et al. 2012

Tidsskriftet

View full text Add to dashboard Cite

Reduction of Immunosuppression for Transplant-Associated Skin Cancer: Rationale and Evidence of Efficacy

Abstract: Reduction of immunosuppression may be an effective adjuvant therapeutic strategy when confronting severe transplant-associated skin cancer. The risks of reduction of immunosuppression must be better defined, and randomized trials of this strategy are necessary.

Cited by 58 publications

References 41 publications

Clinical Findings, Treatments and Outcomes of Transplant Recipients with Metastatic Skin Cancer

Clinical Findings, Treatments and Outcomes of Transplant Recipients with Metastatic Skin Cancer

Polypodium leucotomos: A Potential New Photoprotective Agent

Immunsuppressive legemidler og utvikling av hudkreft etter organtransplantasjon

Contact Info

Product

Resources

About